Reporting sodium channel activity using calcium flux: Pharmacological promiscuity of cardiac Nav1.5

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 207-217

  Zhang, Hongkang ^a,b   Zou, Beiyan ^a,b   Du, Fang ^a,b   Xu, Kaiping ^a,b   Li, Min ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; BUPIVACAINE; CALCIUM ION; FLECAINIDE; LIDOCAINE; LOCAL ANESTHETIC AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ2; PROPAFENONE; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; TERFENADINE; TETRACAINE; TETRODOTOXIN; VERAPAMIL; VOLTAGE GATED SODIUM CHANNEL; CALCIUM; SCN5A PROTEIN, HUMAN; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; ASSAY; BINDING SITE; CALCIUM CURRENT; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG TARGETING; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MEMBRANE ELECTROPHYSIOLOGY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MOLECULAR SENSOR; ACTION POTENTIAL; AMINO ACID SEQUENCE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

ACTION POTENTIALS; AMINO ACID SEQUENCE; CALCIUM; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; SODIUM CHANNEL BLOCKERS;

EID: 84919734312     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094789     Document Type: Article

References (31)

1. Behera S, Krebs M, Loro G, Schumacher K, Costa A, and Kudla J (2013) Ca2+ imaging in plants using genetically encoded Yellow Cameleon Ca2+ indicators. Cold Spring Harb Protoc 8:700-703.
2. Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, Shimizu Y, Janke DL, Parker D, and Mezeyova J et al. (2009) A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev Technol 7:266-280.
3. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, and Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 11:909-922.
4. Bregman H, Berry L, Buchanan JL, Chen A, Du B, Feric E, Hierl M, Huang L, Immke D, and Janosky B et al. (2011) Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. J Med Chem 54:4427-4445.
5. Catterall WA (2012) Voltage-gated sodium channels at 60: structure, function and pathophysiology. J Physiol 590:2577-2589.
6. Edrich T, Wang SY, and Wang GK (2005) State-dependent block of human cardiac hNav1.5 sodium channels by propafenone. J Membr Biol 207:35-43.
7. Erdemli G, Kim AM, Ju H, Springer C, Penland RC, and Hoffmann PK (2012) Cardiac safety implications of hNav1.5 blockade and a framework for pre-clinical evaluation. Front Pharmacol 3:6.
8. Felix JP, Williams BS, Priest BT, Brochu RM, Dick IE, Warren VA, Yan L, Slaughter RS, Kaczorowski GJ, and Smith MM et al. (2004) Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev Technol 2:260-268.
9. Harmer AR, Valentin JP, and Pollard CE (2011) On the relationship between block of the cardiac Na? channel and drug-induced prolongation of the QRS complex. Br J Pharmacol 164:260-273.
10. Huang CJ, Harootunian A, Maher MP, Quan C, Raj CD, McCormack K, Numann R, Negulescu PA, and González JE (2006) Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 24:439-446.
11. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, and Atkinson R et al. (2007) A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 104:8520-8525.
12. Liu CJ, Priest BT, Bugianesi RM, Dulski PM, Felix JP, Dick IE, Brochu RM, Knaus HG, Middleton RE, and Kaczorowski GJ et al. (2006) A high-capacity membrane potential FRET-based assay for NaV1.8 channels. Assay Drug Dev Technol 4:37-48.
13. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, and Côté S et al. (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486:361-367.
14. McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, Krambis MJ, Antonio BM, Zellmer SG, and Printzenhoff D et al. (2013) Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc Natl Acad Sci USA 110:E2724-E2732.
15. Mike A and Lukacs P (2010) The enigmatic drug binding site for sodium channel inhibitors. Curr Mol Pharmacol 3:129-144.
16. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
17. Paredes RM, Etzler JC, Watts LT, Zheng W, and Lechleiter JD (2008) Chemical calcium indicators. Methods 46:143-151.
18. Pérez-García MT, Chiamvimonvat N, Ranjan R, Balser JR, Tomaselli GF, and Marban E (1997) Mechanisms of sodium/calcium selectivity in sodium channels probed by cysteine mutagenesis and sulfhydryl modification. Biophys J 72:989-996.
19. Pérez-Nueno VI and Ritchie DW (2012) Identifying and characterizing promiscuous targets: implications for virtual screening. Expert Opin Drug Discov 7:1-17.
20. Pless SA, Galpin JD, Frankel A, and Ahern CA (2011) Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels. Nat Commun 2:351.
21. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
22. Sunami A, Dudley SC, Jr, and Fozzard HA (1997) Sodium channel selectivity filter regulates antiarrhythmic drug binding. Proc Natl Acad Sci USA 94:14126-14131.
23. Titus SA, Beacham D, Shahane SA, Southall N, Xia M, Huang R, Hooten E, Zhao Y, Shou L, and Austin CP et al. (2009) A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 394:30-38.
24. Trivedi S, Dekermendjian K, Julien R, Huang J, Lund PE, Krupp J, Kronqvist R, Larsson O, and Bostwick R (2008) Cellular HTS assays for pharmacological characterization of NaV1.7 modulators. Assay Drug Dev Technol 6:167-179.
25. Wang GK, Russell C, and Wang SY (2004a) State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 110:166-174.
26. Wang GK and Strichartz GR (2012) State-dependent inhibition of sodium channels by local anesthetics: A 40-year evolution. Biochem (Mosc) Suppl Ser. A Membr Cell Biol 6:120-127.
27. Wang SY, Bonner K, Russell C, and Wang GK (2003) Tryptophan scanning of D1S6 and D4S6 C-termini in voltage-gated sodium channels. Biophys J 85:911-920.
28. Wang SY, Mitchell J, Moczydlowski E, and Wang GK (2004b) Block of inactivationdeficient Na+ channels by local anesthetics in stably transfected mammalian cells: evidence for drug binding along the activation pathway. J Gen Physiol 124:691-701.
29. Yu H, Xu K, Zou B, Wu M, McManus OB, Le Engers J, Cheung YY, Salovich JM, Hopkins CR, and Lindsley CW et al.(2010) Identification of a novel, small molecule inhibitor of KCNQ2 channels, in Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnical Information, Bethesda, MD.
30. Zhao Y, Araki S, Wu J, Teramoto T, Chang YF, Nakano M, Abdelfattah AS, Fujiwara M, Ishihara T, and Nagai T et al. (2011) An expanded palette of genetically encoded Ca2+ indicators. Science 333:1888-1891.
31. Zou B, Yu H, Babcock JJ, Chanda P, Bader JS, McManus OB, and Li M (2010) Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels. Assay Drug Dev Technol 8:743-754.